Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

1.5K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.5K
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

1.6K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.6K
Neural Regulation01:37

Neural Regulation

42.9K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
42.9K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

689
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
689
Amyloid Fibrils03:03

Amyloid Fibrils

11.5K
Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining,...
11.5K
Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders01:27

Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders

1.7K
Schizophrenia is a neurodevelopmental disorder whose origins are rooted in complex genetic components. Despite our burgeoning understanding, the pathophysiology of this disorder remains incompletely deciphered.
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
1.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Muscle Ultrasound Is a Sensitive Outcome Measure in ALS.

Muscle & nerve·2026
Same author

Strategic Amyotrophic Lateral Sclerosis Australia-Systems Genomics Consortium (SALSA-SGC): cohort profile.

BMJ open·2026
Same author

Integration of Serum Neurofilament Light Chain and Cortical Dysfunction Improves Diagnostic Accuracy in ALS.

Annals of clinical and translational neurology·2026
Same author

Monoallelic POLR3A Variants Cause Early-Onset Peripheral Neuropathy.

Annals of neurology·2026
Same author

Cortical changes in amyotrophic lateral sclerosis: comparing biomarkers of glymphatic flow and cortical excitability.

Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology·2026
Same author

Application of a Clinical-Electrophysiological Model for Identifying Chronic Inflammatory Demyelinating Polyradiculoneuropathy in an Australian Cohort.

Journal of the peripheral nervous system : JPNS·2026

Related Experiment Video

Updated: Dec 23, 2025

Real-Time Fluorescent Measurement of Synaptic Functions in Models of Amyotrophic Lateral Sclerosis
08:59

Real-Time Fluorescent Measurement of Synaptic Functions in Models of Amyotrophic Lateral Sclerosis

Published on: July 16, 2021

3.0K

Cortical hyperexcitability evolves with disease progression in ALS.

Parvathi Menon1, Mana Higashihara1, Mehdi van den Bos1

  • 1Westmead Clinical School, University of Sydney, Sydney, NSW, Australia.

Annals of Clinical and Translational Neurology
|April 19, 2020
PubMed
Summary
This summary is machine-generated.

Cortical hyperexcitability increases as amyotrophic lateral sclerosis (ALS) progresses, linked to disease duration. This neurophysiological change involves cortical disinhibition and heightened corticomotoneuronal excitability.

More Related Videos

Evaluation of Hemisphere Lateralization with Bilateral Local Field Potential Recording in Secondary Motor Cortex of Mice
07:03

Evaluation of Hemisphere Lateralization with Bilateral Local Field Potential Recording in Secondary Motor Cortex of Mice

Published on: July 31, 2019

7.1K
In Vivo Electrophysiological Measurement of Compound Muscle Action Potential from the Forelimbs in Mouse Models of Motor Neuron Degeneration
06:35

In Vivo Electrophysiological Measurement of Compound Muscle Action Potential from the Forelimbs in Mouse Models of Motor Neuron Degeneration

Published on: June 15, 2018

20.3K

Related Experiment Videos

Last Updated: Dec 23, 2025

Real-Time Fluorescent Measurement of Synaptic Functions in Models of Amyotrophic Lateral Sclerosis
08:59

Real-Time Fluorescent Measurement of Synaptic Functions in Models of Amyotrophic Lateral Sclerosis

Published on: July 16, 2021

3.0K
Evaluation of Hemisphere Lateralization with Bilateral Local Field Potential Recording in Secondary Motor Cortex of Mice
07:03

Evaluation of Hemisphere Lateralization with Bilateral Local Field Potential Recording in Secondary Motor Cortex of Mice

Published on: July 31, 2019

7.1K
In Vivo Electrophysiological Measurement of Compound Muscle Action Potential from the Forelimbs in Mouse Models of Motor Neuron Degeneration
06:35

In Vivo Electrophysiological Measurement of Compound Muscle Action Potential from the Forelimbs in Mouse Models of Motor Neuron Degeneration

Published on: June 15, 2018

20.3K

Area of Science:

  • Neuroscience
  • Neurology
  • Clinical Neurophysiology

Background:

  • Cortical hyperexcitability is an early indicator in amyotrophic lateral sclerosis (ALS).
  • The progression of cortical hyperexcitability throughout ALS remains incompletely understood.
  • Understanding these changes is crucial for tracking disease advancement and potential interventions.

Purpose of the Study:

  • To investigate the evolution of cortical function in patients with amyotrophic lateral sclerosis (ALS) as the disease progresses.
  • To correlate changes in cortical excitability with disease duration and clinical status.
  • To elucidate the underlying mechanisms of cortical hyperexcitability in ALS.

Main Methods:

  • Prospective study involving 444 patients with suspected ALS (345 ALS, 99 neuromuscular mimics).
  • Cortical function assessed using threshold tracking transcranial magnetic stimulation (TMS).
  • Disease staging based on King's clinical staging system and disease duration tertiles.

Main Results:

  • Cortical hyperexcitability was present across all ALS stages, intensifying in later stages.
  • Increased motor-evoked potential amplitude and prolonged central motor conduction time correlated with disease progression.
  • Reduced short-interval intracortical inhibition, decreased neurophysiological index, and lower compound muscle action potential amplitude were observed with disease duration.

Conclusions:

  • Cortical hyperexcitability significantly increases with disease duration in ALS.
  • This increase is attributed to a combination of cortical disinhibition and enhanced corticomotoneuronal excitability.
  • These findings provide insights into the neurophysiological trajectory of ALS.